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Abstract
Background: Osteoarthritis (OA), the most prevalent disease of articulating joints, is a complex multifactorial disease
caused by genetic, mechanical, and environmental factors. In this research, we evaluated miRNA expression in OA.
Methods: Forty tissue samples from 29 patients undergoing joint replacement for OA were evaluated. Tissue from two
control patients undergoing hip replacement not related to OA was used as a control. Total RNA (containing miRNA
species) from cartilage was isolated using a mirVana miRNA Isolation Kit. Expression of 19 miRNAs was assessed by
real-time quantitative polymerase chain reaction.
Results: Expression of four miRNAs, miR-138-5p, miR-146a-5p, miR-335-5p, and miR-9-5p, was significantly upregulated
in OA tissues (patients vs. control group).
Conclusions: These findings may contribute to disease prevention and the development of therapeutic targets for OA.
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Background
Osteoarthritis (OA) is a complex multifactorial disease
caused by genetic, mechanical, and environmental
factors, and it is the most prevalent disease of the articu-
lating joints. Many environmental factors, such as hor-
mones, diet, infections, injury, alcohol intake, and exposure
to tobacco smoke, are associated with an increased risk of
OA. Exposure of genetically susceptible individuals to such
environmental factors may promote disease development
[1]. Environmental factors induce epigenetic mechanisms
that regulate genomic activity independently of changes in
the DNA sequence and alter the expression of genes
involved in disease development [2]. The three pillars of
epigenetic regulation are DNA methylation, histone modifi-
cation, and non-coding RNA species, including miRNA.
The epigenetic mechanisms involved in the pathogenesis of
OA are not understood [3]. Whether aberrant miRNA
expression is associated with OA development is unclear.
Many recent studies suggested that epigenetic events play a
critical role in OA progression. Moreover, changes in gene
expression have been observed in diseased cartilage [4].
Epigenetic mechanisms occur through miRNA expression.
miRNAs comprise a large family of single-stranded, small,
non-coding RNAs with a sequence length of 19 to 23
nucleotides. These molecules typically bind to the 3′ un-
translated region of their target messenger RNAs
(mRNAs) and repress protein expression by inhibiting
mRNA translation and/or destabilizing mRNA. Micro
RNAs are implicated in many cellular functions, such as
apoptosis, lipid metabolism, malignant transformation,
and differentiation [5].
Joint pain is the primary manifestation of OA. The
complete role of miRNAs in OA is not known. It is
the reason why we decided to extensively study this
task. The prevalence of OA is increasing worldwide,
prompting the search for reliable biomarkers of OA
to aid in drug development. The design of novel
therapeutic strategies, however, will require a better
understanding of the function of differentially expressed
miRNAs, as well as their target genes. In the present
study, we evaluated miRNA expression in OA using real-
time quantitative polymerase chain reaction (qPCR). The
clinical treatment of OA is currently unsatisfactory. The
results of this study provide a better understanding of the
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role of miRNA in OA and may contribute to disease
prevention and the development of more precise
therapeutic targets.
Methods
Sample and clinical data collection was performed at the
Clinical Orthopedics and Traumatology Department of
Clinical Hospital no. 2 in Rzeszow, Poland. Samples
were collected from femoral heads of 29 patients under-
going hip joint replacement planned surgeries of OA
damaged tissue and compared to tissue obtained from
femoral heads of two age-matched healthy patient con-
trols undergoing surgery due to femoral neck fracture.
Cartilage was collected during hospitalization. Writ-
ten informed consent to participate in the study was
obtained from all participants. Critical points for
sample collection were the proper diagnosis of OA
and avoiding collection from sites with total cartilage
loss. Clinical features of the participants were
collected from the medical records based on interview
about general information, previous injuries, BMI,
occupational or sports activities, and clinical manifes-
tations of OA; physical examination; and X-rays
(Table 1). Samples were collected and prepared and
then immediately stored in RNAse-free tubes in a –80 °C
deep freezer until analysis. Ethics approval for this
study was granted by the Bioethical Committee of
the Medical Faculty of Rzeszow University (number:
5/01/2014).
Total RNA isolation
For miRNA profiling, total RNA was purified and
prepared. Total RNA (containing miRNA species) from
cartilage was isolated using a mirVana miRNA Isolation
Kit (Exiqon, Vedbaek, Denmark) following the manufac-
turer’s suggested protocol. For RNA isolated from frozen
cartilage, the integrity and quantity of each sample were
determined using a Bioanalyzer and NanoDrop™.
Micro RNA real-time qPCR
Based on previously published reports and miRNA
databases, we selected 22 miRNAs. In two healthy
controls and 29 patients with OA, we analysed 22 miR-
NAs: let-7e-5p, miR-101-3p, miR-127-5p, miR-130a-3p,
miR-138-5p, miR-146a-5p, miR-16-5p, miR-103a-3p,
miR-423-5p, miR-191-5p, miR-193b-3p, miR-199a-3p,
miR-210-3p, miR-21-5p, miR-222-3p, miR-22-3p, miR-
27a-3p, miR-27b-3p, miR-335-5p, miR-454-3p, miR-
9-5p, and miR-98-5p. The following three miRNAs,
miR-103a-3p, miR-423-5p, and miR-191-5p, were used
as endogenous normalization controls. All of these
three miRNAs are recommended by Exiqon as good
reference genes in cartilage samples and are found to
be the stable normalizers.
Reverse transcription of 10 ng RNA was performed in
10-μl reactions using the miRCURY LNA™ Universal RT
microRNA PCR, Polyadenylation and cDNA Synthesis
Kit (Exiqon, Denmark). The complementary DNA
(cDNA) was diluted 100 times and assayed in 10-μl PCR
reactions according to the manufacturer’s protocol for
miRCURY LNA™ Universal RT microRNA PCR; each
microRNA was assayed once by qPCR on the microRNA
Ready-to-Use PCR, Custom Pick and Mix Panel using
ExiLENT SYBR® Green master mix. Negative controls in
which the template was excluded from the reverse
transcription reaction were processed in the same
manner as the samples. Amplification was performed in
a LightCycler® 480 RealTime PCR System (Roche) in
384-well plates. The amplification curves were analysed
using Roche LC software, both for determination of the
quantification cycle (Cq) by the 2nd derivative method
and for melting curve analysis.
Data analysis
The amplification efficiency was calculated using
algorithms implemented by LinReg software. All assays
were inspected for distinct melting curves, and the
Table 1 Clinical features of the participants
Characteristics OA
Number of participants 29
Sex, male/female 16/13
Age, mean (range) 62.8 (23–83)
Body mass index (mean) 26.74
OA stage: early/late 10/19
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melting temperature was confirmed to be within known
specifications for the assay. Furthermore, the Cq of the
assay had to be 3 Cqs less than that of the negative
control, and less than 37 for the assay to be included in
the data analysis. The Cq was calculated as the 2nd
derivative. Using NormFinder, the best normalizer was
found to be the average of assays detected in all samples
(miR-103a-3p, miR-423-5p, and miR-191-5p). The
following formula was used to calculate the normalized
Cq values: normalized Cq = average Cq (n = 93) − assay
Cq (sample). Relative expression of each gene was calcu-
lated by 2−ΔΔCt formula [6]. The level of miRNA expres-
sion was classified as increased when the fold change is
greater than two [7] (Fig. 1).
Statistical analysis
Statistical analysis was performed using Statistica
12.5PL software (Statsoft, Poland) and PAST software
(ver. 1.57). We compared microRNA expression
between control and patient groups to create nonmet-
ric multidimensional scaling, and then, an analysis of
similarity was performed to evaluate hypothesized
differences between groups of samples using a permutation/
randomisation method of resemblance matrix plots
for each of the datasets [8]. The distribution of vari-
ables was tested using the Shapiro-Wilk test and
Kolmogorov-Smirnov test with Lilliefors correction.
Because of the non-normal distribution of all analysed
variables, we used a non-parametric test, the Mann-
Whitney U test [9].
Results
Multidimensional scaling and analysis of similarity
revealed differences in the expression of all miRNAs
between patients with OA and controls (Fig. 2). Ana-
lysis of similarity indicates a significantly different ex-
pression of mRNA between the two groups (R = 0.315;
p = 0.002). Next, for all 19 miRNAs, the fold change
was calculated. Of the 19 miRNAs, the expression of
4 (hsa-miR-138-5p, hsa-miR-146a-5p, hsa-miR-335-
5p, and hsa-miR-9-5p) was higher than 2-fold change
(OA patients compared with controls, Fig. 1). No
statistically significant relationship was detected
between the clinical data (Table 1) and the miRNA
expression values.
Fig. 1 Cartilage miRNAs with differential expression in osteoarthritis. Mean fold change + standard deviation (SD). Red line cut-off value of fold
change equals two
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Discussion
Micro RNAs regulate diverse aspects of normal physio-
logic conditions. On the other hand, miRNA levels
change in response to pathologic alterations, possibly
contributing to the pathogenesis of degenerative
diseases, such as OA [5]. Therefore, it is important to
determine how miRNA expression is regulated in OA.
Here, we found that the expression of four miRNAs
(hsa-miR-138-5p, hsa-miR-146a-5p, hsa-miR-335-5p,
and hsa-miR-9-5p) was upregulated in OA patients
compared to that in controls (Fig. 3).
miR-146a is one of the first miRNAs reported to be
differentially expressed in OA cartilage. mir-146a is a
crucial determinant in knee joint homeostasis and pain
symptoms associated with OA, maintaining the balance
between the inflammatory response and expression of
pain-associated factors in cartilage glial cells and syno-
vium [10]. Yamasaki et al. [11] reported that miR-146a is
highly expressed in cartilage with a low Mankin grade,
and its expression is decreased in proportion to the level
of matrix metalloproteinase-13 expression. miR-146a is
also expressed in all chondrocyte layers, especially in the
superficial layers, while miR-146a-expressing cells are
lightly distributed in the deep zone, where the matrix
appears normal. Interleukin-1 beta induces the expres-
sion of miR-146a when the first degenerative changes
appear and may play a key role in the inhibition of
catabolic factors through negative feedback, including
downregulation of the adaptor proteins IRAK1 and
TRAF6, in early-stage OA cartilage. In late-stage OA,
expression of miR-146a is low, which leads to progres-
sive degradation of the cartilage due to decreased
suppression of catabolic signals [9].
In our study, expression of miR-138-5p was upregu-
lated which is consistent with the results of Yuan et al.
They suggested that miR-138-5p in interleukin-1 beta
(IL-1β) induced extracellular matrix (ECM) degradation
of OA cartilage. The expression levels of miR-138-5p are
significantly increased in OA cartilage and chondrocytes,
as well as in response to IL-1β stimulation. The results
indicate that miR-138-5p might be involved in the
pathogenesis of OA. miR-138-5p directly modulates the
expression of FOXC1, contributing to IL-1β-induced
ECM degradation in chondrocytes [12].
Patients with OA exhibit early signs of cartilage
degradation, synovial inflammation, and altered bone
structure even before the disease manifests clinically
[13]. Circulating miRNAs are easily accessible and stable
Fig. 2 Multidimensional scaling plot demonstrating differences between patients (red) and controls (green) in expression of all miRNAs examined
(analysis of similarity test R = 0.315; p = 0.002)
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[14, 15], making them convenient for daily clinical moni-
toring. A study of a large cohort representative of the
general community by Beyer et al. [16] provided
evidence that specific miRNAs, such as let-7e, can serve
as valuable biomarkers for OA.
Expression of miR-146a is also reported in OA chon-
drocytes; mechanistically, miR-146a is apparently
responsive to IL-1b signalling and may be involved in
the pain-related pathophysiology of OA [10, 11, 17].
This miRNA was detected in our screening, but was not
differentially expressed between cartilage regions. The
main difference between miR-146a and miR-146b is the
presence of two nucleotides located on different chro-
mosomes. Thus, it is possible that the miRNA homo-
logues mentioned above are differentially regulated
during chondrogenesis and have distinct functions
associated with the control of developmental processes
and maintenance of homeostasis in mature tissue.
In the present study, we reviled increased expression
of miR-9. According to Gu et al. results, targeting of
miR-9 to NF-κβ1 may enhance proliferation and
suppress apoptosis of knee OA chondrocytes through
modification of IL-6 and MMP-13. Moreover, miR-9 and
NF-κβ1 could potentially serve as diagnostic biomarkers
and therapeutic targets for patients with knee OA [18].
Song et al. in their study found that protogenin (PRTG)
is regulated by miR-9, resulting in an inhibition of cell
proliferation and survival in chondrogenic progenitors
and articular chondrocytes. Reduction of miR-9 induc-
tion, which results in increased PRTG levels in OA
pathogenesis, may be responsible for chondrocyte
apoptosis, a typical hallmark of OA [19].
We detected significant changes in the differential
expression patterns of miR-335-5p and the less abundant
3p strand (miR-335*). We have observed a sharp decline
in miR-335-5p expression during transforming growth
factor β3-induced chondrocyte differentiation of hMSCs
(unpublished data), suggesting a potential role for the 5p
strand of miR-335 in regulating genes to maintain a
more progenitor-like phenotype. Supporting this view,
Tome et al. [20] reported that miR-335-5p downregula-
tion is required for MSC differentiation toward the
osteogenic or adipogenic lineage; overexpression of this
miRNA inhibits MSC differentiation. On the other hand,
Zhang et al. [21] reported opposite effects of miR-335-
5p in regulating osteogenesis, but this may be explained
by the fact that they used cell lines as opposed to
primary MSCs. The present study is the first to report
the presence of miR-138 in the cartilage and that higher
expression of this miRNA is associated with differenti-
ated and hypertrophic chondrocytes compared with
precursor cells. These expression patterns suggest a
Fig. 3 Unsupervised hierarchical clustering of differentially expressed miRNAs in the cartilage of the healthy controls and OA patients. Clustering
was performed in all samples. Each row represents one miRNA, and each column represents one sample. The miRNA clustering tree is shown on the
left. Normalized (dCq) values were used in the analysis. The colour scale illustrates the relative level of miRNA expression: red indicates expression level
above the mean (315 times), green represents expression level below the mean (367 times)
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potential role of miR-138 in regulating specific phases of
chondrocyte differentiation. Other studies indicate that
overexpression of miR-138 inhibits osteogenic and
adipogenic differentiation [22, 23]. Interestingly, it has
also been demonstrated that miR-138 promotes induced
pluripotent stem cell generation via regulation of p53
[24], indicating that miR-138 can control cellular
differentiation and may function through different
mechanisms depending on the tissue microenviron-
ment. How this miRNA regulates chondrogenesis and
the mechanisms involved are important questions for
future studies.
Conclusions
Together, the findings of the present study indicate a
correlation between the expression of four miRNAs
(hsa-miR-138-5p, hsa-miR-146a-5p, hsa-miR-335-5p,
and hsa-miR-9-5p) and OA. Changes in the expression of
these four miRNAs were not significantly related to the
clinical data (Table 1) however, or the expression of
selected miRNAs. Therefore, further studies are needed to
assess the usefulness of monitoring cartilage miRNAs for
miRNA-based prognostic and therapeutic approaches.
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